Personalis (NASDAQ:PSNL) CFO Sells $480,400.00 in Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 40,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $12.01, for a total value of $480,400.00. Following the sale, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at approximately $2,387,984.33. This trade represents a 16.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Tachibana also recently made the following trade(s):

• On Friday, May 29th, Aaron Tachibana sold 38,799 shares of Personalis stock. The stock was sold at an average price of $11.58, for a total value of $449,292.42.

Personalis Price Performance

PSNL stock opened at $10.75 on Monday. The business has a fifty day moving average of $7.23 and a two-hundred day moving average of $8.22. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -10.54 and a beta of 2.28. Personalis, Inc. has a 52-week low of $3.84 and a 52-week high of $12.53.

Personalis (NASDAQ:PSNL) last posted its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The business had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.49 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. As a group, sell-side analysts anticipate that Personalis, Inc. will post -1.06 EPS for the current year.

Institutional Trading of Personalis

A number of institutional investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. increased its position in shares of Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after purchasing an additional 7,896,714 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Personalis by 1,332.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock worth $11,531,000 after purchasing an additional 1,347,439 shares in the last quarter. Kennedy Capital Management LLC increased its position in shares of Personalis by 196.2% during the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after purchasing an additional 1,281,695 shares in the last quarter. Aberdeen Group plc increased its position in shares of Personalis by 36.1% during the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after purchasing an additional 861,948 shares in the last quarter. Finally, ARK Investment Management LLC increased its position in shares of Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after purchasing an additional 802,268 shares in the last quarter. 61.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on PSNL shares. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a research report on Saturday, May 30th. Morgan Stanley lowered their price target on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. BTIG Research lowered their price target on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Finally, Needham & Company LLC raised their price target on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Personalis has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.